Trials / Completed
CompletedNCT02160353
Neo-adjuvant Abiraterone Prostate Study
Phase II Single-arm Study Evaluating Neo-adjuvant (Pre-radical Radiotherapy) Abiraterone Acetate (Plus Prednisolone) and Gonadotropin-Releasing Hormone (GnRH) Agonist in High Risk Localised Prostate Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Cancer Trials Ireland · Network
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abiraterone acetate, Prednisolone |
Timeline
- Start date
- 2015-07-09
- Primary completion
- 2021-01-19
- Completion
- 2021-01-19
- First posted
- 2014-06-10
- Last updated
- 2026-04-13
Locations
3 sites across 1 country: Ireland
Source: ClinicalTrials.gov record NCT02160353. Inclusion in this directory is not an endorsement.